Inhibitors of alpha L beta 2 integrin mediated cell adhesion

Compounds of formula (I), wherein R is hydrogen atom, hydroxyl group or carbamoyl group, and n is 1 or 2, are disclosed. A process for the preparation of a compound of formula (I) is also described. Compounds of formula (I) are useful in the manufacture of a medicament for the treatment or prevention of a LFA-1 mediated condition in a patient. This condition may be an inflammatory disease, an autoimmune disease or an allergic disease. These compounds are also useful in the manufacture of a medicament for the treatment or prevention of a condition caused or mediated by substance P in a patient. This condition may be an inflammatory disease.